Research
Filter News
Found 142,651 articles
-
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
5/3/2023
Convergent Therapeutics Inc. today announced the completion of a $90 million Series A financing, led by OrbiMed and RA Capital Management with participation from Invus.
-
ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab
5/3/2023
The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported today by Eli Lilly and Company for their amyloid-clearing antibody donanemab.
-
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts
5/3/2023
The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination.
-
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
5/3/2023
Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) and Dianthus Therapeutics, Inc. (“Dianthus”), a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
-
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
5/3/2023
Vertex Announces U.S. FDA Approval for KALYDECO ® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older.
-
Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration
5/3/2023
Forge Biologics, a leading manufacturer of genetic medicines, today announced a gene therapy development and manufacturing collaboration with Labcorp (NYSE: LH), a leading global life sciences company.
-
PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft Investigatng New Dosing Regimen for Patients With Polycythemia Vera (PV)
5/3/2023
PharmaEssentia USA Corporation today announced that the first patients are now being dosed in ECLIPSE PV, a Phase 3b clinical study evaluating an accelerated dosing schedule for ropeginterferon alfa-2b-njft using a prefilled syringe for the treatment of adults with polycythemia vera (PV).
-
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline
5/3/2023
NImmune Biopharma today announced the launch of a research collaboration with the NIMML Institute (“NIMML”), a nonprofit institute dedicated to the discovery of novel immune-mediated precision medicines.
-
Alnylam Issues 2022 Corporate Responsibility Report
5/3/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report.
-
ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)
5/3/2023
ARTHEx Biotech S.L. announced the closing of its €42 million Series B financing round led by Columbus Venture Partners, with participation from new investors, the European Innovation Council (EIC), Hadean Ventures, and Sound Bioventures.
-
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
5/3/2023
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS ® (Voclosporin) For Adults with Active Lupus Nephritis.
-
Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy
5/3/2023
Zevra Therapeutics, Inc. today announced the acceptance of an Investigational New Drug (“IND”) application by the U.S. Food and Drug Administration (“FDA”) to begin a Phase 1 clinical trial of KP1077 in narcolepsy which is expected to provide additional information regarding the optimal dosing regimen.
-
Microbot Medical’s LIBERTY® Robotic System Surpasses 100th Catheterization
5/3/2023
Microbot Medical Inc. announced the system has surpassed its 100th catheterization during multiple pre-clinical studies, with a 95% success rate of reaching pre-determined vascular targets, such as distal branches of hepatic, gastric, splenic, mesenteric, renal, hypogastric arteries.
-
NuProbe BDA Technology Enables Highly Sensitive Detection of Low-Level Variants for Oncology Research
5/3/2023
NuProbe, a genomics company developing ultrasensitive research assays for detecting and monitoring low-frequency mutations, gene fusions, and copy number alterations (CNAs), recently published research demonstrating capabilities of their blocker displacement amplification (BDA) technology for detection of a JAK2 mutation using qPCR.
-
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies
5/3/2023
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent, multi-center study in the Archives of Dermatological Research providing a direct chain of evidence that use of DecisionDx®-Melanoma test results to guide radiological surveillance could lead to improved patient outcomes.
-
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
5/3/2023
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy.
-
Gate Neurosciences Hones in on Precision Medicine with Expanded Research Operations Supporting Its Synaptic Function-Enhancing Molecules
5/3/2023
Gate Neurosciences announced it has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois.
-
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
5/3/2023
Eli Lilly and Company announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease.
-
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
5/3/2023
Soleno Therapeutics, Inc. announced that it has completed enrollment in the randomized withdrawal period of Study C602, a long-term treatment study of DCCR Extended-Release tablets for the treatment of Prader-Willi syndrome.
-
Hyundai Bioscience announced positive phase 2 clinical study results of the global blockbuster candidate for the COVID-19 antiviral drug
5/3/2023
Hyundai Bioscience announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug 'Xafty'.